Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
The health care giant said Friday that it will spend $335 in cash for each share of Shockwave. The total deal value includes cash acquired.
The deal has already been approved by the boards of directors from both companies.
Founded in 2009, Shockwave focuses on intravascular lithotripsy technology that uses sonic pressure waves to crack calcium lesions in arteries and restore blood flow. It’s similar to a technique used to break up kidney stones. The soundwave emitters are placed inside angioplasty catheters to reach the calcified areas of the artery.
Shockwave’s technology is used to treat coronary artery and peripheral artery disease.
The company’s revenue jumped 49% last year to $730 million.
US overdose deaths dropped in 2023, the first time since 2018
John Adams' Nativity oratorio 'El Nino' gets colorful staging at the Met
Alabama lawmakers advance bill to strengthen state's weak open records law
Alabama lawmakers advance bill to strengthen state's weak open records law
Haleigh Bryant helps LSU gymnastics advance to team finals at NCAA women’s championship
A reset at running back might look different for the Cowboys 8 years after drafting Ezekiel Elliott
MLB suspends Pirates Aroldis Chapman, fines him for 'inappropriate actions'
Cruise worker 'murders newborn son on board ship': Shocked co
Carlos Carrasco pitches solid into the 6th inning, Guardians edge Red Sox 5
Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
Rural Texas towns report cyberattacks that caused one water system to overflow